Compare Ecolab Inc. (ECL) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Medpace Holdings Inc — how do they compare? Ecolab Inc. trades at $285.5 (market cap $79.79B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Ecolab Inc. is far larger — about 4.7× Medpace Holdings Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| ECL | MEDP | |
|---|---|---|
Market Cap | $79.79B | $16.90B |
Sector | Consumer Cyclical | Technology |
52-Week High | $308.35 | $620.59 |
52-Week Low | $245.73 | $393.42 |
Enterprise Value | $88.57B | $16.52B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $281.17, down 1.14% on the day, with a bullish technical signal from moving averages and strong institutional interest. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance to $8.05-$8.25. Revenue growth remains steady at 5% organic, supported by pricing gains and volume increases. Valuation ratios are elevated with a P/E of 38.21, reflecting premium pricing for consistent performance.
Outlook is positive with a consensus price target of $327.90, implying 16.6% upside. Risks include high valuation sensitivity and rising input costs. The stock offers growth potential from digital expansion and recent CoolIT acquisition, but investors should monitor margin pressures and debt levels.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
